A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors (NCT05836324)

🧪 Interventions in This Study

• INCA33890 (DRUG)
• bevacizumab (DRUG)
• FOLFIRI (DRUG)
• FOLFOX (DRUG)
• Cetuximab (DRUG)
• ADG126 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (39 Sites)

Showing the first 25 of 39 sites.

• The Angeles Clinic and Research Institute — Los Angeles, California
• Valkyrie Clinical Trials — Los Angeles, California
• Dana Farber Cancer Institute — Boston, Massachusetts
• Cancer and Hematology Centers of Western Michigan-Start Midwest — Grand Rapids, Michigan
• Hackensack University Medical Center — Hackensack, New Jersey
• Nyu Langone Health - Long Island Hospital — Mineola, New York
• Laura and Isaac Perlmutter Cancer Center — New York, New York
• University of Pennsylvania — Philadelphia, Pennsylvania
• Lifespan Cancer Research Institute — Providence, Rhode Island
• University of Texas Md Anderson Cancer Center — Houston, Texas
• South Texas Accelerated Research Therapeutics — San Antonio, Texas
• Cancer Hospital Chinese Academy of Medical Sciences — Beijing,
• Peking University People'S Hospital — Beijing,
• The First Affiliated Hospital, Zhejiang University School of Medicine (Fahzu) — Hangzhou,
• Rigshospitalet Uni of Hospital of Copenhagen — Copenhagen,
• Herlev Og Gentofte Hospital — Herlev,
• Odense University Hospital — Odense C,
• Vejle Hospital — Vejle,
• Centre Leon Berard — Lyon,
• Institut Gustave Roussy — Villejuif,
• Fondazione Irccs Istituto Nazionale Dei Tumori — Milan,
• Irccs Istituto Clinico Humanitas — Rozzano,
• Centro Ricerche Cliniche Di Verona — Verona,
• Kansai Medical University Hospital — Hirakata,
• National Cancer Center Hospital — Tokyo,

📞 Contact the Study Coordinator

Phone: (855) 463-3463

Email: medinfo@incyte.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
• A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
• Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
• Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.